🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
3.310
-0.070 (-2.07%)
Nov 18, 2026, 10:50 AM EST - Market open
← View all transcripts

Jefferies Global Healthcare Conference

Nov 16, 2026

Summary

EoE is now the lead indication for the 052 bispecific, with a larger study planned and a target of faster, broader response. The 2138 oral lichen planus study has started, while 9494 is moving toward filing and 2027 proof of concept.

Roger Song
Senior Equity Research Analyst, Jefferies

[inaudible] to 2026 Jefferies Global Healthcare Conference in London. My name is Roger Song, Senior Analyst, covers biotech. It is my pleasure to have a fireside chat with our company, Aclaris Therapeutics, and we have our CEO, Neal, and CMO, Jesse. Welcome, gentlemen.

Neal Walker
CEO, Aclaris Therapeutics

Thank you. Thank you for having us.

Roger Song
Senior Equity Research Analyst, Jefferies

Awesome. Maybe, Neal, can you just give us state of art of Aclaris? You just announced two news this morning, and where are you now, and where heading to, why you are excited about 2027? Thank you.

Neal Walker
CEO, Aclaris Therapeutics

Sure. This morning we put out two press releases, one announcing that bosakitug, which is our TSLP monoclonal antibody, did not hit the endpoint in atopic dermatitis. This was a little bit of a flyer for us. We were just testing out. We know that TSLP mAb in the past hasn't done well in AD as single agent therapy, and clearly we've shown with the bispecific that the additive benefit of both is important. While disappointing on the clinical front, we did see robust PD responses across the board, particularly on Th1, Th17, and Th2, which was very consistent with the work we did with the bispecific. That was never in our base case plan. Moving forward, our base case plan was to engage in BD on that front.

But yeah, we put that out this morning.

In addition, we also announced on the oral small molecule side that we have initiated the 2138 modzatinib study in oral lichen planus. That kicked off last week.

We are excited about that. Going forward into 2027, and one other thing, we did also comment on the ITK next- gen that we have been talking about.

We have made it through all of the tox required tox. Now it is just about pressing the button and filing that this quarter, so that will be in the coming weeks. We are excited about that. Both of those oral small molecule programs open up a lot of value coming into 2027. Moving forward now, we have already talked about, in the last couple weeks, prioritizing EoE as the lead indication for the 052 bispecific. Then we have the 2138 LP study up and running, and that will be in all three phenotypes of lichen planus, mucosal, skin, and scalp.

Advancing the ITK next-gen through SAD/MAD work and into POC in 2027.

Roger Song
Senior Equity Research Analyst, Jefferies

Excellent. Okay. As you said, I do not think it is that surprising this TSLP alone is not specifically working in the AD. Honestly, you are bold enough to run this trial, and then because you have a probably good TSLP monoclonal antibody. My question is, how much you learn from that phase two, along with your previous single arm trial, and then how much you learn from that, and then you have a higher or lower confidence for your bispecific using the similar construct of the TSLP?

Neal Walker
CEO, Aclaris Therapeutics

Yeah, I still would say it is very high on that front. The ATI-052 data, to me, leveraging the power of the bispecific was unequivocal, and we did take a little bit of a flyer. We did a very small study just to look at the TSLP mAb. The original plan was to do a bigger dose-ranging study. I am glad we did not. I think the fact that it did show activity, it just did not quite have the horsepower, kind of makes sense with the disease. If you leave IL-4 and IL-13 untouched-

To keep inflaming the tissue, then it turns out that perhaps TSLP itself does not have enough horsepower to just get it across the finish line. But then when you look at the bispecific construct and you know that IL-4, 13 are leaving some efficacy on the table, what the TSLP is able to do is just take out the front end of that inflammatory cascade, that amplification loop, and then squash that remaining inflammation. We certainly saw that in all of the immune proteome work where we normalized the skin proteome with the bispecific, and we are just getting some of this data in, so I will just comment a little bit on it. We got some Olink data out of the Guttman lab that showed really, really strong biomarker suppression on TH1, TH17, and also on TH2.

I think my conclusion at the end of the day was maybe similar to what a lot of folks thought going in, and I think we definitively answered the question about the single agent therapy.

Roger Song
Senior Equity Research Analyst, Jefferies

Yeah. Okay. Got it. Basically, the drug that we're supposed to do, but just not really addressing the full spectrum of the atopic dermatitis.

Neal Walker
CEO, Aclaris Therapeutics

That's correct. Yep.

Roger Song
Senior Equity Research Analyst, Jefferies

Okay. I think we can move on from that. Now since we're on that topic, talk about the bispecific, it's TSLP and IL-4 receptor. We know that's on the opposite side. Teze just reported positive data in the EOE, and that probably one of the key reason you want to go after. Maybe just give us a little bit of biology. Why TSLP could work EOE versus others? I think that TSLP works in respiratory disease, but how about the GI? Why you think so far we don't have that many developments in the EOE for the TSLP? Just because Teze is the first one going to validate that, or how you think about the field will evolve from here?

Neal Walker
CEO, Aclaris Therapeutics

Yeah, I think maybe I'll start and then Jesse can add in. I think the field is definitely evolving. We've talked to a ton of KOLs over the course of the last two, three months, and there's a pretty clear consensus that EoE is becoming more and more prevalent. In fact, some of these folks are predicting that you'll pretty soon see prevalence over one million patients, and basically making some strong statements around following the course of IBD, which is interesting. As you know, just historically, folks tried IL-5s, and it turns out that hitting just the eosinophil itself just isn't enough. In fact, what we've learned from some of these conversations is when you look at these histo readings, most people just see the eos per high power field, but what they really are looking at is the entire inflammatory burden.

That's what these guys track when they look at histo over the course of 52 weeks. Clearly, TSLP would have an advantage there in terms of hitting some of these inflammatory pathways. I think since the early days, they've learned that there's a genetic association with TSLP. So there's a lot of great scientific early-stage reasons to believe in that mechanism. We know Dupixent's approved, and now we have this data that Teze generated, and our molecule kind of reads on both. Maybe, Jesse, if you want to comment additionally.

Jesse Hall
CMO, Aclaris Therapeutics

Yeah, so absolutely. The output for the tezepelumab CROSSING program was important for us. Going into the phase I-B readouts, we always had the plan that we were going to be looking at EoE. We were looking at potentially a smaller study. Given the fact that now TSLP is validated in that indication, we feel even more compelled to run a larger study and focus the bispecific program on EoE initially. Yeah.

Neal Walker
CEO, Aclaris Therapeutics

Yeah. I think, one of the keys that we've learned is also just kind of the slew of people report out DSQ and they report out eos per high power field. But on the histo side, what has been flagged as important to us is the complete inflammatory cascade on histology. That was the problem with benralizumab, right? All it did was take out the eosinophil. It didn't do anything to all the other inflammatory mediators. Very different with Dupi and Teze. So, I think that's an important piece when you think about how does one differentiate on histo score. Then, the other measures, like DSQ is kind of a blunt object, so there's a lot of other kind of PRO endpoints that are important to the docs and the patient.

Depending on who you talk to, whether it's an allergist or a GI doc, endoscopy is critically important. I always kind of wondered before learning about this, if you want to see a response, you look at the skin, right? If you're in dermatology. Well, GI doc, you look at the pictures of the esophagus, and that was flagged as a key component. One of the things that has resonated over and over is just speed of response. What they're not seeing with either of these two agents is kind of a speed component, and they're kind of getting to the same place by week 52. Certainly, we think that's a huge opportunity to differentiate if you have a dual modality approach.

Roger Song
Senior Equity Research Analyst, Jefferies

I see. Okay. The target profile is you can get to the efficacy a little bit earlier, and then the level of efficacy you are expecting will be comparable or slightly higher. What's the target profile compared to Teze alone and then Dupixent alone?

Neal Walker
CEO, Aclaris Therapeutics

Yeah. We'd like to see speed. We'd like to see more depth of response. There's kind of two ways to think about a higher responder rate. One is, are you truly driving depth, or are you getting breadth out of the patient population? Are you picking up patients that you wouldn't otherwise pick up if you were using single agents alone? We've seen this in some recent case reports where a patient might have a middling response to Dupi and then magically get just quite a bit better on Teze. My guess is we're going to see the same thing that we've already proven out in our 052 1b studies and the other studies.

Roger Song
Senior Equity Research Analyst, Jefferies

Okay. Got it. All right. Just step back. 052 is probably the first bispecific during the TSLP trial for doing that EoE. Any uniqueness, maybe just highlight the uniqueness of 052. You think you may be better suited than other bispecific for EoE?

Neal Walker
CEO, Aclaris Therapeutics

Well, I think so far, the most direct read-through would be that Dupi works, Teze works, we're infinitely more potent than Teze, and we have this bispecific construct. The dosing interval piece, I think with Dupi administered, at least on label, Q weekly is an issue. I think roping that into the program, testing out the longer dosing intervals will be important. We anticipate doing an induction and kind of maintenance kind of construct.

Roger Song
Senior Equity Research Analyst, Jefferies

Okay. Got it. All right. Then, you are going to run the phase two next year. So what's the current thinking about the design? As you said earlier, different ways to measure the benefit of the disease, and then maybe a bispecific can have a different benefit. Just give us a little bit high-level thoughts of the design.

Jesse Hall
CMO, Aclaris Therapeutics

Yeah. Absolutely. We think that this initial study with the bispecific in EoE will be important to capture the broad spectrum response. So we're going to be looking at histologic outcome measures, we're going to be looking at symptom outcome measures, and then we're also going to be looking at endoscopic outcome measures. We think it's the total package that we'll be evaluating with regards to endpoints for this initial EoE study. The goal for the study will be to run an efficient design, meaning moving from the phase II to the registrational portion as rapidly as possible, and the design will reflect that speed.

Roger Song
Senior Equity Research Analyst, Jefferies

Okay. Got it. Then I remember when you prioritized the EoE, you were thinking about second indication. Now with the bosakitug, this data, how we think about, are you still committed to the second indication, or you want to reserve some capital for other programs?

Neal Walker
CEO, Aclaris Therapeutics

We're going to guide to that before the end of the year, and we'll continue to. The other two 1b studies are still ongoing, and then we're still sifting through some of the bosa work itself. I don't, although I wanted the bosa to be stat sig, I'm not surprised by it, so I don't think it has that much of an influence. The two studies are testing different concepts, but we'll provide further guidance on that before the end of the year.

Roger Song
Senior Equity Research Analyst, Jefferies

Is that the choice between the asthma and the atopic dermatitis, or something else beyond those three indications?

Neal Walker
CEO, Aclaris Therapeutics

I think it's really between those two, and I think one of the things we're thinking about is doing a study design that, in one of the two, that perhaps incorporates a positive control, so that you are more definitive or maybe taking Dupi failures in, something akin to a little bit what Pfizer's thinking about. I think it's becoming increasingly difficult to do these cross-trial comparisons on such disparate datasets as we've talked about extensively. Our 052 study in AD encompassed very, very severe patients, which is quite different in why I was so happy with that result. But perhaps if you're not in the derm field, it's not fully appreciated. The only other way to kind of definitively show something is do either a prior single therapy failure study or do a positive control.

Roger Song
Senior Equity Research Analyst, Jefferies

Okay. Basically, you want to choose one indication among those two with some design to show the benefit.

Neal Walker
CEO, Aclaris Therapeutics

Yep.

Roger Song
Senior Equity Research Analyst, Jefferies

Okay, got it. All right. I think a lot of investors really focus on your ITK/ JAK3 for lichen planus, for the right reason. Maybe just to remind us the study design, and then also specifically how you power for ODSS at the 16-week interim.

Neal Walker
CEO, Aclaris Therapeutics

All right. Do you want to talk about the design?

Jesse Hall
CMO, Aclaris Therapeutics

Yeah, absolutely. We're really excited about this lichen planus indication, and we're getting a lot of enthusiasm from investigators as well as patients as we're speaking about it. The design is a basket cohort design, and the reason we call it a basket design is there'll be multiple subtypes. The main subtypes that will be included are the mucosal, the cutaneous, and then the scalp form, which is the lichen planopilaris. We're also taking it in a cohort-by-cohort fashion. The initial cohort will be the oral component, and then we'll move subsequently to the cutaneous and the LPP. The primary endpoint for the clinical study will be ODSS. So ODSS is the Oral Disease Severity Score, originally developed for oral pemphigoid, subsequently adapted and validated in oral lichen planus. We have a 16-week endpoint.

The goal is to enroll somewhere between 35 and 40 patients, with an interim analysis after about 60% of patients have reached the week 16 endpoint. We're also going to be including the IGA score, because there is some interest potentially from a regulatory perspective that IGA may become the default endpoint in that. So we want to understand what the powering will look like for the phase three study. We'll also be looking at patient-reported outcomes as well. But great news to now be able to say and to announce that we've initiated that study, and we're really looking forward to progressing through that clinical study next year.

Roger Song
Senior Equity Research Analyst, Jefferies

Got it. At interim, as you said, you have a certified 240 patient, they will look at the ODSS. First of all, how many endpoints you will look at at the interim for those subgroup of the patient? Then the two is, in that statistic, you are going to see some statistics from that interim, given the smaller sample size?

Jesse Hall
CMO, Aclaris Therapeutics

Yeah, so absolutely. For the initial interim, we will be looking at all of the relevant endpoints, so including ODSS, IGA, as well as the patient-reported outcomes. The study is powered, and we have powered it based on ODSS. We will communicate further what exactly the expectations are. The reason we like ODSS is it is a continuous outcome measure. It goes from 0- 106, meaning it is very sensitive to change, which means we were able to power the study with a fairly reasonable sample size for the initial cohort.

Roger Song
Senior Equity Research Analyst, Jefferies

Got it. Then you say powered, because it is phase two, it is not like you have some alpha penalty at the interim. Its power is 0.05 or 0.1, and what kind of power are you thinking?

Jesse Hall
CMO, Aclaris Therapeutics

Yeah. So, we are looking at it from the perspective of a reasonable powered study for that size. ODSS, again, as I mentioned, is that continuous variable, very sensitive to change, and we are able to power the study on a very small number of subjects.

Roger Song
Senior Equity Research Analyst, Jefferies

Okay. Then, I believe your goal is to report the interim and talk with the FDA, potentially can expand that into the pivotal. You say you will guide the explanation later, but just what will be sufficient data for FDA to allow you to expand to the pivotal?

Jesse Hall
CMO, Aclaris Therapeutics

Yeah, no, it's a great question. We were very interested in pursuing this path, and we were very happy to see the engagement from the FDA with the Fast Track designation. I think what that allows us is additional interaction with the agency moving forward. The plan would be, once we have the interim analysis data in hand, is to go back to the agency and discuss what the registrational program will look like.

Neal Walker
CEO, Aclaris Therapeutics

Yeah, I think whenever you have an indication like this, where patients are suffering with moderate to severe disease, I mean, you think about having canker sores all over your mouth, I mean, it's pretty distressing. The fact that we got Fast Track designation for this allows us this flexibility and opportunity. We think, look, if you just look at the literature, we think we're going to see responses quite a bit earlier than week 16. It'll always be the kind of aggregate of the efficacy and safety data to push to the next level. But we're quite confident in being able to do that.

Roger Song
Senior Equity Research Analyst, Jefferies

Mm-hmm. Yeah. Okay. Then we know we don't have approved drug yet, but also maybe some of the other JAK also want to do this similar kind of indication. How we think about, on one side, the clinically meaningful benefit, also competitively, how you think your—

Neal Walker
CEO, Aclaris Therapeutics

Sure.

Roger Song
Senior Equity Research Analyst, Jefferies

—can do.

Neal Walker
CEO, Aclaris Therapeutics

There's not a great amount of double-blind placebo control data out there. Obviously, a lot of good case reports, things like that. I think when you think about mechanistic match, that's when we get really excited because LP is driven through an antigenic stimulation of the T-cell receptor. The only way to take that out is to hit upstream at the ITK level, just like cyclosporine might do. Mechanistically, there's just not another compound out there that has the same value prop. I think we feel good about that component. In terms of just what we feel is a reasonable kind of table stakes, when you look at ODSS, if you're seeing something like a 50% response, I think that would be pretty compelling.

You're very unlikely in these sorts of patients at the moderate to severe end of the spectrum with particular mucosal. This is not a waxing or waning disease. This is a disease that kind of comes and smolders for years and years and years. I think that gives us a pretty good feeling going in.

Roger Song
Senior Equity Research Analyst, Jefferies

Mm-hmm. How much is the placebo effect which you expect? Because it's small sample size and when we look at it.

Neal Walker
CEO, Aclaris Therapeutics

Yeah, I mean, I can't really give you a great answer because there hasn't been a ton of work done in this area. There has been a recent study that was just published using a topical corticosteroid versus placebo. The caveat is they did this in patients with very mild disease. But even with that, it was, I think, a 20% response rate. So even at the mild end of the spectrum, exceedingly low just by—

Roger Song
Senior Equity Research Analyst, Jefferies

Yeah.

Neal Walker
CEO, Aclaris Therapeutics

—if I compare to AD, you know? They were able to generate a nice spread with a small number of patients just with that. That's why we're choosing kind of the IgA 3s and 4s, because you don't want to. That's in stark contrast to cutaneous. As an example, cutaneous tends to wax and wane over time. It's a little bit more unpredictable than mucosal.

Roger Song
Senior Equity Research Analyst, Jefferies

Got it. Then you say 20% is the ODSS.

Neal Walker
CEO, Aclaris Therapeutics

Correct. Yep.

Roger Song
Senior Equity Research Analyst, Jefferies

All right. That trial is also topical at the placebo.

Neal Walker
CEO, Aclaris Therapeutics

Yeah, that was topical, and it was much milder.

Roger Song
Senior Equity Research Analyst, Jefferies

Yeah.

Neal Walker
CEO, Aclaris Therapeutics

They had, comparatively, they had ODSS scores at baseline that were much lower.

Roger Song
Senior Equity Research Analyst, Jefferies

Got it.

Neal Walker
CEO, Aclaris Therapeutics

But that was just published, like, what, a week ago?

Jesse Hall
CMO, Aclaris Therapeutics

Yeah, just very recently.

Neal Walker
CEO, Aclaris Therapeutics

Yeah.

Roger Song
Senior Equity Research Analyst, Jefferies

Got it. LP did not have any approved drug, and then your ITK also hit the JAK3. Then I believe in the past, talking about the etopidomutide, you're thinking maybe the base case, you're going to have a black box and a box warning, just like all the JAK. So how do you think about the LP, how likely you will get the black box warning, how likely you will remove? Then for this indication, you think it will be acceptable?

Neal Walker
CEO, Aclaris Therapeutics

Yeah, I mean, I always have to go with the conservative base case, right? Because you're not going to get that answer till review time. I do think that over the course of the years since the tofa data, and if you just look with a very keen eye at the labels of a lot of these drugs, they're all a little bit different. Not every black box is the same. I don't worry too much about that in the context of this indication. Nothing's approved. Right now, we're treating these patients with things like cyclosporine, prednisone, Plaquenil, which has And people forget this, like Plaquenil has retinal toxicity and liver issues and all sorts of bad things. So, I think if you catch a black box that has a warning or a risk about infection, I think you would count yourself lucky in that regard.

Roger Song
Senior Equity Research Analyst, Jefferies

Got it. Okay, just lastly, you also are advancing your selective ITK program, 9494. So where's the timeline look like? Then, because it is hitting high, just upstream, as you said, the ITK, what's the indication selection, then what's the development plan going to look?

Neal Walker
CEO, Aclaris Therapeutics

We're looking at TH2-based indications, and we're really thrilled that we've checked all the boxes on the tox front and looking forward to filing that in the coming weeks. The next step would be the SAD/MAD work, and we'll try to incorporate some patients in the MAD work that have some disease, perhaps some elevated FeNO levels where we can pick up some early looks, and then we advance to POC. So, I think the indications, we haven't totally decided on those yet, but they would be TH2-based and looking at things like atopic or asthma as an oral.

Roger Song
Senior Equity Research Analyst, Jefferies

Got it. Is it TH2 or TH1? You say earlier, you say it's TH1.

Neal Walker
CEO, Aclaris Therapeutics

TH2.

Roger Song
Senior Equity Research Analyst, Jefferies

TH2. Okay, got it. All right. I think my time's up, then thank you.

Thank you so much, everyone, and thank you

Neal Walker
CEO, Aclaris Therapeutics

Sure

Roger Song
Senior Equity Research Analyst, Jefferies

Neal and Jesse.